Q&A with hVIVO’s Mo Khan
Episode 1609, Sep 12, 2023, 09:20 AM
hVIVO’s Mo Khan: “we are seeing revenue fully contracted well into next year”
Mo Khan, chief executive of hVIVO, talks to Vox Markets about what’s behind the company’s blockbuster half-year results and an upgrade of its full year sales and profit forecasts, and the commitment to a new regular dividend.
In this interview, hVIVO chief executive Mo Khan talks to Vox about what’s behind the company’s blockbuster half-year results and an upgrade of its full year sales and profit forecasts, including the development of new human challenge models and a continued focus on driving operational efficiency, underpinned by a move to a new state-of-the-art facility.
0:37 Mo Khan discusses the highlights of the strong half-year results.
2:08 How the diversification of the business across new challenge models and the expansion of the scope of its services is underpinning scalable growth.
4:20 Real world examples of how human challenge models are accelerating the drug delivery process at large biopharma companies.
7:10 The success in scaling up the business, including recent news of a new facility to conduct human challenge trials to be opened
9:09 How a focus on operational efficiency is driving margin expansion, and the impact of the new facility
9:52 The strong outlook with revenue visibility stretching well into 2024, and what’s behind the upgrade of sales and profit outlook, and introduction of a new regular dividend.
Mo Khan, chief executive of hVIVO, talks to Vox Markets about what’s behind the company’s blockbuster half-year results and an upgrade of its full year sales and profit forecasts, and the commitment to a new regular dividend.
In this interview, hVIVO chief executive Mo Khan talks to Vox about what’s behind the company’s blockbuster half-year results and an upgrade of its full year sales and profit forecasts, including the development of new human challenge models and a continued focus on driving operational efficiency, underpinned by a move to a new state-of-the-art facility.
0:37 Mo Khan discusses the highlights of the strong half-year results.
2:08 How the diversification of the business across new challenge models and the expansion of the scope of its services is underpinning scalable growth.
4:20 Real world examples of how human challenge models are accelerating the drug delivery process at large biopharma companies.
7:10 The success in scaling up the business, including recent news of a new facility to conduct human challenge trials to be opened
9:09 How a focus on operational efficiency is driving margin expansion, and the impact of the new facility
9:52 The strong outlook with revenue visibility stretching well into 2024, and what’s behind the upgrade of sales and profit outlook, and introduction of a new regular dividend.